| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1000118158 |
| P356 | DOI | 10.1007/S12072-010-9207-1 |
| P932 | PMC publication ID | 2994618 |
| P698 | PubMed publication ID | 21286343 |
| P5875 | ResearchGate publication ID | 49803087 |
| P50 | author | David K Wong | Q57123619 |
| P2093 | author name string | E Jenny Heathcote | |
| Venessa Pattullo | |||
| P2860 | cites work | Genotyping Hepatitis C Viruses from Southeast Asia by a Novel Line Probe Assay That Simultaneously Detects Core and 5' Untranslated Regions | Q27477772 |
| Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1 | Q27478313 | ||
| A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C | Q27478337 | ||
| Exploring differences in response to treatment with peginterferon alpha 2a (40kD) and ribavirin in chronic hepatitis C between genotypes 2 and 3 | Q27485351 | ||
| Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection | Q27860901 | ||
| Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial | Q27860949 | ||
| Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance | Q28255243 | ||
| Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose | Q29547886 | ||
| Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies | Q29614505 | ||
| IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy | Q29614896 | ||
| Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C | Q29619541 | ||
| Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials | Q34100819 | ||
| Type 2 diabetes prevalence in Asian Americans: results of a national health survey | Q34286031 | ||
| Chronic hepatitis C virus genotype 6 infection: response to pegylated interferon and ribavirin. | Q34801283 | ||
| High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. | Q35206324 | ||
| Elevated expression and polymorphisms of SOCS3 influence patient response to antiviral therapy in chronic hepatitis C. | Q40078224 | ||
| Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response | Q42978643 | ||
| Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. | Q42978706 | ||
| Factors affecting early viral load decline of Asian chronic hepatitis C patients receiving pegylated interferon plus ribavirin therapy. | Q42986432 | ||
| Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection | Q42989510 | ||
| Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. | Q42991111 | ||
| Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection | Q42992027 | ||
| Pegylated interferon plus optimized weight-based ribavirin dosing negate the influence of weight and body mass index on early viral kinetics and sustained virological response in chronic hepatitis C. | Q42995136 | ||
| Tumor necrosis factor- alpha promoter polymorphism at position -308 predicts response to combination therapy in hepatitis C virus infection | Q42996968 | ||
| Changing prevalence of hepatitis C virus genotypes: molecular epidemiology and clinical implications in the hepatitis C virus hyperendemic areas and a tertiary referral center in Taiwan | Q43033806 | ||
| Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment | Q43034816 | ||
| Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1. | Q43040978 | ||
| Inferior response of Asian vs non-Asian hepatitis C genotype 3 infection to combination antiviral therapy | Q43047742 | ||
| Human leukocyte antigen class I and II alleles and response to interferon-alpha treatment, in Taiwanese patients with chronic hepatitis C virus infection | Q43047952 | ||
| Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors | Q43048213 | ||
| Similar treatment response to peginterferon and ribavirin in Asian and Caucasian patients with chronic hepatitis C. | Q43244698 | ||
| Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. | Q44643929 | ||
| Impact of asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C. | Q46866205 | ||
| Differences in treatment outcome for hepatitis C among ethnic groups | Q46920864 | ||
| Race, insulin resistance and hepatic steatosis in chronic hepatitis C. | Q50574540 | ||
| Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. | Q50579007 | ||
| P433 | issue | 4 | |
| P921 | main subject | ribavirin | Q421862 |
| pegylated interferon | Q7160835 | ||
| chronic hepatitis | Q62019625 | ||
| P304 | page(s) | 723-731 | |
| P577 | publication date | 2010-08-08 | |
| P1433 | published in | Hepatology international | Q26842730 |
| P1476 | title | Superior response to pegylated interferon and ribavirin in Asians with chronic hepatitis C | |
| P478 | volume | 4 |
| Q41912262 | Body mass index and nonresponse to antiviral treatment in korean patients with genotype 2 and 3 chronic hepatitis C. |
| Q30417045 | Consensus Statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part II: INASL Recommendations for Management of HCV in India |
| Q35201293 | Evidence-based clinical guidelines for immigrants and refugees |
| Q36269670 | Hepatitis C virus infection: Are there still specific problems with genotype 3? |
| Q50554397 | Pegylated interferon α-2b plus ribavirin for Japanese chronic hepatitis C patients with normal alanine aminotransferase. |
| Q89890370 | Pharmacogenomics in Asian subpopulations and impacts on commonly prescribed medications |
| Q38098579 | Psychological, lifestyle and social predictors of hepatitis C treatment response: a systematic review |
| Q37646759 | Real-world experience with interferon-free, direct acting antiviral therapies in Asian Americans with chronic hepatitis C and advanced liver disease |
| Q36009336 | Sustained Virologic Response to a Dual Peginterferon alfa-2a and Ribavirin in Treating Chronic hepatitis C Infection: A Retrospective Cohort Study |
Search more.